Our correlation analyses of the relationship between estimated excitability values in the whole-brain models and these independent AD biomarkers may suggest that functional readjustments are attempted in parallel to Aβ and tau pathological spread and the loss of neurons in the human brain. This evidence concerns the gene MAPT and Alzheimer disease.